Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma By Ogkologos - March 16, 2026 65 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Respuestas a sus preguntas sobre la vacuna contra el COVID-19 March 12, 2021 New on NCI’s Websites for November 2024 November 1, 2024 FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia September 3, 2021 Insights Into the Biology of Response and Resistance to MAPK Pathway... October 16, 2024 Load more HOT NEWS FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment Will This Cancer Metastasize? Check Its “Stickiness” Life beyond cancer: Improving the long term side effects for children... A Deep-Learning Model Predicts the Primary System Origin of Malignant Cells...
